Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

your body attacks its acetylcholine receptors. Myasthenia gravis is considered to be an autoimmune disorder. In an autoimmune disease, some of the body's antibodies (special proteins in your body ...

In the case of myasthenia gravis, the body produces autoantibodies that target acetylcholine receptors (AChRs), which are essential triggers for normal muscle contraction functions.

Ocular MG is a milder form of generalized MG, with lower AChR titers and less aggressive treatment needs. AChR titers above 100 nmol/L at diagnosis predict progression from ocular to generalized MG.

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

gMG is different from ocular myasthenia gravis, which only affects the eye muscles. “Anti-acetylcholine receptor (AChR) antibody-positive” means your immune system makes antibodies that block ...

in adults living with generalized myasthenia gravis (gMG). The results demonstrated durable and sustained efficacy of UPLIZNA in patients with acetylcholine receptor autoantibody-positive (AChR+ ...

"All three types of myasthenia gravis ... ryanodine receptor, collagen Q, and cortactin -- have been suggested as potential binding sites for antibodies that cause weakness.